ArticleJournal of autism and developmental disorders2025
Efficacy of Antioxidant-Based Pharmacological Therapies in Autism Spectrum Disorder: A Systematic Review.
Article in Journal of autism and developmental disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAutism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by persistent deficits in social interaction and communication. This study aimed to evaluate the efficacy of antioxidant-based pharmacological therapies for psychiatric symptoms in patients with ASD.
methodsA systematic review was conducted using four databases: PubMed, Scopus, ClinicalTrials.gov and Cochrane - Ovid. 20 studies were included. Risk of bias assessment was performed using the Cochrane Risk-of-Bias tool for randomized trials. A descriptive analysis synthesized the main findings. A qualitative value was given to each antioxidant therapy according to its effect on every symptom (improved, not improved or no information), data was visually reported using ChatGPT 4.0 and Google Collab. PROSPERO ID: CRD42023490581.
resultsThere was a heterogeneous response to antioxidant therapies for ASD symptoms. The use of sulforaphane reported improvement in irritability, stereotypic/repetitive behavior, social cognition/interaction, social communication, hyperactivity and lethargy. Similarly, N-Acetylcysteine evidenced improvement in terms of irritability, stereotypic/repetitive behavior, social cognition and hyperactivity. L-Carnosine improved social cognition and communication, omega-3/omega-6 fatty acids improved social cognition, coenzyme q-10 showed improvement in sleep disorders, and glutathione in repetitive behaviors and irritability.
conclusionAntioxidant-based pharmacological therapy evidenced contrasting responses to a variety of core symptoms in ASD. Despite significant evidence of improvement in some ASD symptom scales, there is still a lack of evidence to justify the use of antioxidant therapies as monotherapy in individuals with ASD.
Indexed as
Identifiers
41071465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.